BioSpace News Archive

Cosmos Holdings, Inc., an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, announced that it will be presenting at the Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. ET.

Dr. Almas is a board-certified pathologist with years of experience in hospitals, independent laboratories, and Centers for Medicare & Medicaid Services.

TRIMEDX, an industry-leading, technology-enabled provider of clinical engineering, medical device cybersecurity, and clinical asset management solutions, announced new features that will help healthcare systems reduce medical device cybersecurity risks, bolster patient safety, and optimize medical equipment across all sites of care.

Several factors including age, genetics, lifestyle, and family history, personal history of breast cancer, dense breast tissue, menstrual periods and menopause are responsible for the development of breast cancer.

At this year’s American Academy of Orthopaedic Surgeons annual meeting, which is being held March 22 to 26 in Chicago, HSS presented new research related to biomechanics and orthopedic surgery, highlighting the unique relationship surgeons have with the engineers to promote the highest quality in patient care and advancing joint replacement for the future.

Monoclonal antibodies targeting the inhibitory receptors Cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death protein 1 (PD-1) have emerged out to be potential target in the management of cancer.

Revolo Biotherapeutics, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced that its management team will be attending the SVB Leerink Biopharma Private Company Connect being held virtually from March 29-31, 2022.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that new interim data from 2nd line NSCLC patients (Part B) of its phase II TACTI-002 trial has been published in an abstract today in advance of ESMO’s European Lung Cancer Congress (ELCC) 2022.

Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the fourth quarter and full year ended December 31, 2021, and a corporate update.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.